Drug intelligence / Profile preview

Noclot

Development stage: Unknown
Lead developer: Biomet
Administration: Oral

Overview

Noclot, specifically known by its product name noClot-50, is an FDA-approved anticoagulant and blood-processing product. It is a small volume anticoagulant that was originally developed by Cytosol Laboratories. The product was strategically acquired by Biomet to ensure a critical supply component for its proprietary platelet separation and concentration systems, such as GPS® III and BioCue™. Biomet also expressed intentions to explore additional clinical applications for noClot-50, particularly in areas like granulocytapheresis and the enhancement of stored red blood cells.

Brand names: noClot-50noClot50noClot 50

Targets

P2Y12 (Purinergic P2Y12 receptor)

Beyond the preview

Go deeper on Noclot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noclot.

Explore the full profile